Chemomab Therapeutics Ltd.
CMMB
$3.42
-$0.0558-1.60%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 975.00K | 802.00K | 840.00K | 896.00K | 2.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.26M | 3.21M | 3.77M | 4.05M | 9.05M |
| Operating Income | -2.26M | -3.21M | -3.77M | -4.05M | -9.05M |
| Income Before Tax | -2.06M | -2.96M | -3.63M | -3.87M | -8.73M |
| Income Tax Expenses | -- | -- | -- | -- | 21.00K |
| Earnings from Continuing Operations | -2.06M | -2.96M | -3.63M | -3.87M | -8.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.06M | -2.96M | -3.63M | -3.87M | -8.75M |
| EBIT | -2.26M | -3.21M | -3.77M | -4.05M | -9.05M |
| EBITDA | -2.25M | -3.20M | -3.75M | -4.03M | -9.03M |
| EPS Basic | -1.78 | -3.14 | -5.08 | -5.44 | -15.84 |
| Normalized Basic EPS | -0.06 | -0.10 | -0.16 | -- | -0.49 |
| EPS Diluted | -1.78 | -3.14 | -5.08 | -5.44 | -15.84 |
| Normalized Diluted EPS | -0.06 | -0.10 | -0.16 | -- | -0.49 |
| Average Basic Shares Outstanding | 23.18M | 18.86M | 14.30M | 14.21M | 11.05M |
| Average Diluted Shares Outstanding | 1.16M | 942.80K | 715.20K | 710.30K | 552.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |